Tampa General Hospital is the best hospital of the Tampa Bay region and is a leading academic medical center that is ranked among the top centers nationally.

The Department performs basic and translational scientific research, as well as clinical research. Our basic and translational research includes:

1. Structure and mechanism of molecular predictors of IPF and COVID-19 mortality – Principal Investigator: Dr. Jose D. Herazo-Maya
2. Structural, genetic, and functional determinants of G-protein coupled receptors (GPCRs) relevant to biological function in lung and heart – Principal Investigator: Dr. Stephen Liggett

(Our department is currently enrolling patients in clinical research.)

Medication Trials

• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of Pulmonary Arterial Hypertension
• A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients with Pulmonary Hypertension due to Chronic Obstructive Pulmonary Disease (PH-COPD)
• A Phase 3, 2-Part, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Liposomal Treprostinil Inhalation Suspension (L606) in Subjects With Pulmonary Arterial Hypertension Previously Stabilized on Inhaled Treprostinil Products
• A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by Cardiopulmonary Exercise Testing in Subjects with World Health Organization Group 1 Pulmonary Hypertension Who Recently Initiated Therapy (ADVANCE Capacity)
• A Study Evaluating the Long-term Efficacy and Safety of Ralinepag in Subjects with PAH via an Open-label Extension (ADVANCE-Extension)

Registries

• An International, non-drug interventional, real world cohort of PAH patients newly initiating PAH therapy with guideline directed assessment of disease
• ADAPT - A Patient Registry of the Real-world Use of Orenitram®
• RiOciguAt UseRs Registry – The ROAR registry

Medication Trials

• A Phase 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex
• A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease

Our fellowship requires a minimum of 6 months of dedicated research time for each fellow. The fellows participate in a variety of projects, including basic, translational, clinical, and quality projects.